Logo

Pete Martinez, MJ Soileau, Les Croland, Weaver Gaines, Marshall Criser, David Day, John Fraser, Fred Lippman, Erik Sander, Bill Newman, Carla Rathbun, Raymond Cheung, Carol Pratt

Feb 27, 2008
Premium
The Florida Research Consortium this week announced the election of officers and executive committee members for 2008.
 
Pete Martinez of the Quantum Group has been named chairman; MJ Soileau of the University of Central Florida, vice-chairman; Les Croland of Edwards Angell Palmer & Dodge, secretary; Weaver Gaines of Nanotherapeutics, treasurer; and Marshall Criser of AT&T Florida, immediate past chairman.
 
Elected to join the officers on the FRC executive committee in at-large positions include David Day of the University of Florida; John Fraser of Florida State University; Fred Lippman of Nova Southeastern University; and Erik Sander of the V2R Group and UF.
 
 
The Oregon Bioscience Association this week said that Bill Newman has been named chairman of its board of directors for 2008. Newman is managing director with Northwest Technology Ventures.
 
Other OBA board officers for the year are Carla Rathbun, secretary and consultant, and Raymond Cheung, treasurer, both from Geffen Mesher & Co.; and Carol Pratt, legal counsel at K& L Gates.

Breaking News
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.